Figure 2From: Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study Distribution of absolute change in burden of disease (BOD) from baseline to week 48 in the two treatment groups. For presentation purposes, two patients receiving interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw), were removed from this plot; one patient had an extreme increase from baseline value of 56868.5 mm3 and another had an extreme reduction from baseline of 23453.6 mm3 percent changes in BOD. im, intramuscular; qw, once weekly.Back to article page